Meiji Becomes First in Japan to Introduce Bifidobacterium in Infant Formula
In a groundbreaking development for infant nutrition, Meiji Co., Ltd. has gained significant approval for incorporating bifidobacterium into its infant formula products, namely the 'Meiji Hohoemi' and 'Meiji Step' brands. This marks a first in Japan as no infant formula has previously included this beneficial bacterium, recognized for its crucial role in supporting infant health. Scheduled to be available from November 25, 2025, for 'Meiji Hohoemi' and around spring 2026 for 'Meiji Step', these new offerings reflect Meiji's commitment to ensuring optimal growth and health for infants and young children.
Bifidobacterium is a vital component of an infant's gut flora, especially prevalent in babies before weaning. The specific strain that Meiji will use, named 'Bifidobacterium OLB6378', has been meticulously selected from around 300 strains in the company’s library for its health benefits for infants. The strain is derived from infants, emphasizing its tailored approach to infant care. Such strains are known to help facilitate positive digestion, improve immune responses, and ensure a healthier start in life.
Microscopic view of Bifidobacterium OLB6378
Research conducted by Meiji has uncovered a growing trend among parents opting for milk-only child-rearing methods. However, concerns regarding adequate nutrition and immunity in children have also surfaced, reflecting an increasing need among parents to ensure their children receive necessary nutrients for healthy growth. The approval to include bifidobacterium in their infant formula is part of Meiji’s response to these needs, aiming to support infant health with scientifically backed nutrition.
Meiji's studies highlight that many parents are increasingly worried about whether they are providing sufficient nutrition for their children. This has translated into a demand for products that not only nourish but also bolster the immune system, particularly in the critical early stages of life.
The integration of bifidobacterium into these formulas is expected to set new standards in the Japanese market for infant nutrition. The expected release dates for both 'Meiji Hohoemi' and 'Meiji Step' are set after thorough testing and marketing strategies to ensure consumer trust and product efficacy.
With the launch of these new products, Meiji plans to enhance the packaging design to better communicate the quality, safety, and nutritional value of the formulas. The packaging will reflect the brand's commitment to transparency and consumer education, making it easier for parents to understand the benefits of the new formulations.
Moving forward, Meiji Co., Ltd. is dedicated to continuing its research on quality and safety, ensuring that parents can confidently provide their children with nutrition that promotes healthy growth and development. As the landscape of child-rearing evolves, Meiji aims to support an environment that makes parenting smoother and more effective for families across Japan.
Understanding Bifidobacterium OLB6378
Bifidobacterium is a vital component of an infant's gut flora, especially prevalent in babies before weaning. The specific strain that Meiji will use, named 'Bifidobacterium OLB6378', has been meticulously selected from around 300 strains in the company’s library for its health benefits for infants. The strain is derived from infants, emphasizing its tailored approach to infant care. Such strains are known to help facilitate positive digestion, improve immune responses, and ensure a healthier start in life.
Microscopic view of Bifidobacterium OLB6378
Background Behind the Approval and Product Development
Research conducted by Meiji has uncovered a growing trend among parents opting for milk-only child-rearing methods. However, concerns regarding adequate nutrition and immunity in children have also surfaced, reflecting an increasing need among parents to ensure their children receive necessary nutrients for healthy growth. The approval to include bifidobacterium in their infant formula is part of Meiji’s response to these needs, aiming to support infant health with scientifically backed nutrition.
Understanding Parental Concerns Over Children’s Health
Meiji's studies highlight that many parents are increasingly worried about whether they are providing sufficient nutrition for their children. This has translated into a demand for products that not only nourish but also bolster the immune system, particularly in the critical early stages of life.
Product Release Overview and Expected Launch Date
The integration of bifidobacterium into these formulas is expected to set new standards in the Japanese market for infant nutrition. The expected release dates for both 'Meiji Hohoemi' and 'Meiji Step' are set after thorough testing and marketing strategies to ensure consumer trust and product efficacy.
Design and Packaging Changes
With the launch of these new products, Meiji plans to enhance the packaging design to better communicate the quality, safety, and nutritional value of the formulas. The packaging will reflect the brand's commitment to transparency and consumer education, making it easier for parents to understand the benefits of the new formulations.
- - Meiji Hohoemi 780g
Moving forward, Meiji Co., Ltd. is dedicated to continuing its research on quality and safety, ensuring that parents can confidently provide their children with nutrition that promotes healthy growth and development. As the landscape of child-rearing evolves, Meiji aims to support an environment that makes parenting smoother and more effective for families across Japan.
Topics Consumer Products & Retail）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.